ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease a nested case-control study

JAMA Cardiology

Volumn 3, Issue 5, 2018, Pages 401-408

  Nissen, Steven E ^a   Pillai, Sreekumar G ^b   Nicholls, Stephen J ^c,d   Wolski, Kathy ^a   Riesmeyer, Jeffrey S ^b   Weerakkody, Govinda J ^b   Foster, Wendra M ^b   Mcerlean, Ellen ^a   Li, Lin ^e   Bhatnagar, Pallav ^b   Ruotolo, Giacomo ^b   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e BioStat Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALCETRAPIB; EVACETRAPIB; PLACEBO; ADENYLATE CYCLASE; ADENYLATE CYCLASE 9; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADCY9 GENE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; GENETICS;

ADENYLYL CYCLASES; AGED; ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85049086288     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2018.0569     Document Type: Article

References (8)

1. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
2. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.
3. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al; ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933-1942.
4. HPS3/TIMI55-REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017; 377 (13): 1217-1227.
5. Business Wire. Merck provides update on anacetrapib development program. https://www.businesswire.com/news/home/20171011006286/en/Merck-Update-Anacetrapib-Development-Program. Published October 11, 2017. Accessed February 21, 2018.
6. Tardif JC, Rhéaume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015; 8 (2): 372-382.
7. Tardif JC, Rhainds D, Brodeur M, et al. Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circ Cardiovasc Genet. 2016; 9 (4): 340-348.
8. Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. Am Heart J. 2015;170(6):1061-1069.